0001209191-19-000406.txt : 20190102
0001209191-19-000406.hdr.sgml : 20190102
20190102175656
ACCESSION NUMBER: 0001209191-19-000406
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181228
FILED AS OF DATE: 20190102
DATE AS OF CHANGE: 20190102
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Menzaghi Frederique Ph.D.
CENTRAL INDEX KEY: 0001597152
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36279
FILM NUMBER: 19502935
MAIL ADDRESS:
STREET 1: C/O CARA THERAPEUTICS, INC.
STREET 2: 1 PARROTT DRIVE
CITY: SHELTON
STATE: CT
ZIP: 06484
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cara Therapeutics, Inc.
CENTRAL INDEX KEY: 0001346830
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4 STAMFORD PLAZA
STREET 2: 107 ELM STREET 9TH FLOOR
CITY: STAMFORD
STATE: CT
ZIP: 06902
BUSINESS PHONE: 203-406-3700
MAIL ADDRESS:
STREET 1: 4 STAMFORD PLAZA
STREET 2: 107 ELM STREET 9TH FLOOR
CITY: STAMFORD
STATE: CT
ZIP: 06902
FORMER COMPANY:
FORMER CONFORMED NAME: Cara Therapeutics Inc
DATE OF NAME CHANGE: 20051213
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-12-28
0
0001346830
Cara Therapeutics, Inc.
CARA
0001597152
Menzaghi Frederique Ph.D.
C/O CARA THERAPEUTICS, INC.
4 STAMFORD PLAZA, 107 ELM ST, 9TH FLOOR
STAMFORD
CT
06902
0
1
0
0
Sr VP-Research & Development
Common Stock
2018-12-28
4
S
0
4300
12.53
D
146479
D
This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting and of the restricted stock units reported in the Form 4 filed by the Reporting Person with the Securities and Exchange Commission on December 31, 2018, and does not represent a discretionary trade by the Reporting Person.
Represents the number of shares required to be sold by the Reporting Person to cover tax withholding described above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.50 to $12.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
/s/Darren DeStefano, Attorney-in-Fact
2019-01-02